touchONCOLOGY publishes two peer-reviewed, free-to-access journals, that aim to provide insightful and topical articles relevant to the day-to-day practice of busy physicians. View our latest and archive content below.
More information about our journals along with how to submit your work can be found here.
COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia: What Can We Expect?
touchREVIEWS in Oncology & Haematology. 2021;17(1):Online ahead of journal publication
Advanced age and other comorbid conditions put patients with chronic lymphocytic leukaemia (CLL) at an increased risk of morbidity and mortality from SARS-CoV-2 infection, with early studies showing case fatality rates of over 30% in patients with CLL with symptomatic COVID-19.1,2 As the vaccination against COVID-19 is becoming available for use in the general population, its […]
Pexidartinib and CSF1R Inhibitors as Treatment for Tenosynovial Giant Cell Tumors
Oncology & Hematology Review (US). 2020;16(2):119-23 DOI: https://doi.org/10.17925/OHR.2021.16.2.119
Tenosynovial giant cell tumor (TGCT)—previously referred to as giant cell tumor of the tendon sheath or pigmented villonodular synovitis (PVNS)—is a largely benign, rare, proliferative lesion arising from the synovial lining of joints, bursae, and tendon sheaths.1 This review serves to discuss the epidemiology, molecular biology, clinical behavior, and the current treatment modalities of TGCT that […]
Latest Developments in Cellular Therapy for Multiple Myeloma
Oncology & Hematology Review (US). 2020;16(2):111-8 DOI: https://doi.org/10.17925/OHR.2021.16.2.111
Multiple myeloma (MM) is a malignant clonal disorder of plasma cells in the bone marrow, and more than 32,000 new cases are expected in the USA each year.1 Many clinical advances, including novel drugs and continuous therapy with treatment sequencing, have improved survival statistics.2 Despite this, MM remains largely incurable and the relapsed/refractory population remains vulnerable […]
Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma
Oncology & Hematology Review. 2020;16(2):90–4 DOI: https://doi.org/10.17925/OHR.2021.16.2.90
Esophageal cancer is the seventh most common malignancy and the sixth leading cause of death from cancer worldwide.1 The main histological subtypes are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the most common subtype, and the frequency of this disease is highest in Eastern Asia and Eastern Africa.2 In Western countries, however, the incidence […]
New Approaches to Allogeneic Hematopoietic Cell Transplantation
Oncology & Hematology Review (US). 2020;16(2):Online ahead of journal publication
**This manuscript has been accepted for publication, but not yet copyedited or typeset, and may be subject to minor changes during the production process.**
Testicular Choriocarcinoma with Inexplicably High Beta-human Chorionic Gonadotropin and Renal Metastases
Oncology & Hematology Review (US). 2020;16(2):124-6 DOI: https://doi.org/10.17925/OHR.2021.16.2.124
Choriocarcinoma of the testes is very rare, occurring either in pure form or as part of mixed germ cell tumor.1,2 Pure choriocarcinoma constitutes <1% of choriocarcinoma cases, whereas mixed tumors with choriocarcinoma make up 8% of testicular germ cell tumors.2 The overall incidence of choriocarcinoma is 0.8 cases per 100,000 male population in countries with highest frequency […]
Evolving Therapies for Urothelial Carcinoma—Novel Paradigms and Future Directions
Oncology & Hematology Review. 2020;16(2):82-9 DOI: https://doi.org/10.17925/OHR.2021.16.2.82
Urothelial carcinoma is the most common histologic type of bladder cancer in the USA and Europe, accounting for 90% of all bladder cancers. It is the sixth most common type of cancer diagnosed in the USA, and the 10th leading cause of cancer death, with an estimated 17,980 deaths predicted in 2020.1 Although the 5-year survival […]
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances
Oncology & Hematology Review (US). 100-10 DOI: https://doi.org/10.17925/OHR.2021.16.2.100
Advanced non-small cell lung carcinoma (NSCLC) treatment paradigms have evolved during the past decade. Identification of tumor-specific molecular alteration in cancer driver genes has led to the development of targeted therapies.1–3 Most of the tumors harboring such alterations are sensitive to tyrosine kinase inhibitor (TKI) drugs, making such oncogenic drivers promising targets for the development of […]
Radiation-induced Esophagitis in Lung Cancer—A Common Problem with Limited Therapeutic Options
Oncology & Hematology Review. 2020;16(2): 95-99 DOI: https://doi.org/10.17925/OHR.2021.16.2.95
Radiation-induced esophagitis, caused by incidental damage to the mucosal lining of the esophagus during radiation therapy, is a common and clinically important toxicity in patients with lung cancer. Esophagitis generally develops 2–3 weeks after initiation of radiation therapy and presents as pain and dysphagia, which can negatively impact patient quality of life.1 Severe esophagitis requires parenteral […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!